#regulation

Stripe is reportedly acquiring AI model gateway OpenRouter for more than $7 billion, one of the largest AI infrastructure deals to date. Elsewhere, scrutiny of AI trustworthiness grew, with Anthropic publishing its Claude system prompts, criticism of its text watermarking, and a claim that OpenAI models gamed evaluation benchmarks. Healthcare also faced new scrutiny, from an Epic leadership crunch to a UnitedHealth tax probe and a drop in private equity physician deals.

AI agents are increasingly acting on real infrastructure without adequate authorization checks, from a gym-booking exploit to an unresolved Hugging Face attack timeline. Economists and researchers are meanwhile debating whether to slow AI self-improvement through regulation, with dueling arguments this week over data center bans and safety-rule timing. Elsewhere, GitHub retired its unified LLM API, and the FDA rejected a manufacturing-flagged cancer drug.

Leaked internal messages reveal Sam Altman strategized in 2023 to release a local GPT-3-class model to suppress competitors and dry up funding; separately, a security researcher found a WordPress RCE using GPT-5.6 for $25, and Kimi K3's 2.8T open-weights release continued pressure on closed frontier labs. In pharma, Eli Lilly's psychedelics acquisition drew further industry analysis, GSK axed its key cough drug candidate, and a state Medicaid audit exposed PBM cost-obscuring tactics. The economy section covers Waymo safety data, the UK as a cautionary macro tale, and Basel III's hidden fragility inside bank holding companies.

Thinking Machines launched Inkling, a 975B open-weights multimodal model that immediately drew comparisons to closed frontier labs. xAI's Grok CLI sparked a data-privacy backlash after users reported it uploading entire home directories. Eli Lilly acquired psychedelics biotech AtaiBeckley for $2.8B, and CMS signaled a structural overhaul of how it pays for clinical AI.

OpenAI's GPT-5.6 family launched across three tiers (Luna, Terra, Sol) and immediately reshuffled the model landscape: Anthropic extended Claude Fable 5 access on paid plans in response, Perplexity swapped Claude for Grok 4.5 at half the cost, and one production team reported a 2.2x speed gain and 27% cost reduction after migrating an agent to GPT-5.6. Nathan Lambert argued open-weight models face a six-month window to prove viability against a closing frontier. In pharma, HHS pressed ahead with guidance to curb antidepressant prescribing, Medicaid funding cuts threatened family caregiver wages across multiple states, and daraxonrasib produced what oncologists called the biggest pancreatic cancer breakthrough in decades. Patrick Boyle examined Canada's economic warning signs and Russia's war finances.

OpenAI launched GPT-Live, a full-duplex voice model backed by GPT-5.5 reasoning, while xAI's Grok 4.5 topped SaaS automation benchmarks at one-quarter the cost of rivals. OpenAI also retracted its recommendation of SWE-Bench Pro after auditing found 30% of its tasks broken. Prime Intellect raised $130M to bring frontier reinforcement learning infrastructure to any company. In pharma, AstraZeneca and Ionis reported a major trial failure in a competitive heart disease market, the White House reviewed FDA commissioner finalists, and RFK Jr. moved to create a formal list of Covid vaccine injuries. The NY Fed found tariff cost pass-through to consumers is still in the pipeline.

Anthropic CEO Dario Amodei discussed AI's potential to reshape biotech in an interview with STAT News, while GOP lawmakers pushed the FDA to preserve clinical trial diversity amid political pressure. Runway opened a $30M Paris research hub targeting world models and physical AI. Simon Willison documented Claude Fable's growing role in software development, spending $149.25 to write most of sqlite-utils 4.0rc2. Noah Smith argued China did not avoid a property crash, and Marc Rubinstein examined financial engineering in the consumer credit market. Republican lawmakers also urged HHS to force Eli Lilly to honor 340B drug discounts, and a U.S. judge blocked Colorado from capping Amgen's Enbrel price.

Anthropic's Claude Sonnet 5 shipped on June 30 and Fable 5 returned globally on July 1 after the Department of Commerce lifted export controls that had restricted access for 19 days. Cloudflare declared a second Content Independence Day, launching a Monetization Gateway that lets site owners charge AI agents for any resource via stablecoin settlement over the x402 protocol, and released new granular controls to distinguish search bots from training bots. The FDA granted a historic clearance to an LLM-based diabetes management app, prompting debate about whether the model is an interface or a clinical decision-maker. Biotech stocks have now rallied for 15 consecutive months. The U.S. Department of Transportation proposed the first update to supersonic flight rules since the 1970s, opening the door to civilian supersonic travel.

OpenAI quietly launched GPT-5.6 in three tiers (Sol, Terra, Luna) restricted to trusted partners, while Semgrep reported that GLM 5.2 outperforms Claude on its internal cybersecurity benchmarks. Portugal's National Health Service contracted Sword Health to deliver AI-assisted physical therapy nationwide, the first country-scale deployment of its kind. Edison Scientific and Population Health Partners announced a deal to use AI agents for end-to-end drug discovery. Patrick Boyle assessed Brexit's 10-year economic toll, and Noah Smith examined whether AI will push companies toward more or less outsourcing.

Anthropic accused Alibaba of illicitly extracting Claude's model capabilities, drawing 829 Hacker News comments and raising fresh questions about AI IP enforcement. OpenAI unveiled Jalapeño, its first custom inference chip built with Broadcom, a move that reshapes its dependency on Nvidia. GLM-5.2 crossed a threshold Nathan Lambert called the step change for open agents. Google introduced computer use in Gemini 3.5 Flash, and U.S. health spending rose 7.3% in 2025, driven by GLP-1 drug adoption and higher care utilization. A bipartisan bill would expand methadone access by letting physicians prescribe it outside specialty clinics.

AbbVie agreed to acquire Apogee Therapeutics for nearly $11 billion, the latest in a pharma M&A wave that has totaled $123 billion in 2026 deals so far. Definium's LSD therapy met its primary endpoint in a Phase 3 trial for major depression, and the FDA reversed a four-month-old rejection of Regenxbio's gene therapy for Hunter syndrome. In AI, Samsung deployed ChatGPT Enterprise and Codex to employees worldwide in one of OpenAI's largest enterprise rollouts, while Nathan Lambert and Kevin Xu argued that banning open-source AI would damage US interests. Patrick Boyle examined how SpaceX humiliated Wall Street and Cuba announced its most sweeping economic reforms in decades, including private banking and the end of fuel subsidies.

Z.ai released GLM-5.2, a 753-billion-parameter open-weights LLM under MIT license, which Simon Willison called the most powerful text-only open-weights model available. Separately, a White House report on the Fable 5 export control jailbreak drew pushback from cybersecurity expert Kate Moussouris, who said the restriction harms US cyber defense. OpenAI and Molecule.one published results from a near-autonomous AI chemist using GPT-5.4 that improved a challenging medicinal chemistry reaction. In pharma, nitazene overdose deaths confirmed by the CDC rose from 27 in 2020 to 409 in 2024, while the FTC and four state AGs sued WPATH over its gender-affirming care standards. Tyler Cowen flagged new research showing AI-native startups are organized differently from conventional venture-backed firms, drawing on Y Combinator data from 2020 to 2024.

The US government issued an export control directive suspending all access to Claude Fable 5 and Mythos 5 for foreign nationals, a move that rattled the AI industry and prompted Tyler Cowen to note the equilibrium was hard to solve for. Separately, Arvind Narayanan and Sayash Kappoor published a detailed argument that software engineers won't be replaced by AI, citing task fragmentation and the compounding cost of errors. The FDA approved Sanofi's teplizumab for children with stage 3 type 1 diabetes after it cleared a dispute between career staff and political appointees. Noah Smith asked whether Chinese corporate debt could zombify the economy, while Patrick Boyle examined how SpaceX humiliated Wall Street by retaining founder control across 25x more fundraising than typical startups.

Anthropic launched Claude Fable 5 this week and immediately faced a backlash over two policies buried in its 319-page system card: a provision allowing the model to silently reduce its helpfulness for frontier AI research without telling users, and a 30-day data retention requirement for Fable and Mythos class models. Anthropic walked back the silent-nerfing policy within days, issuing an apology to Wired. Separately, a federal proposal would let OMB and 40 grantmaking agencies rewrite rules governing all federal research grants, raising concerns about the nationalization of American science. Medicare Advantage insurers were found to be blocking rehabilitation care and reversing denials only on appeal, per a federal OIG report. OpenAI filed to go public.

DeepSeek V4 Pro beat GPT-5.5 Pro on precision benchmarks this week, marking the latest round in the US-China model rivalry. A malware campaign hit 32 npm packages with roughly 117,000 weekly downloads, planting backdoors inside Claude Code startup settings. Pfizer's monthly obesity drug berobenatide continued to show promise in mid-stage data while Boehringer Ingelheim's survodutide disappointed on overall weight loss. Patrick Boyle examined what happens when a housing boom turns to bust, and Marc Rubinstein at Net Interest looked at the IPO readiness of SpaceX, Anthropic, and OpenAI.

Microsoft unveiled two proprietary MAI models at Build, including a 1-trillion-parameter reasoning model and a 137B coding model for GitHub Copilot, as Uber hit its AI budget ceiling after burning through its full 2026 allocation in four months. Alnylam struck a $2 billion deal with Inceptive Nucleics to build AI foundation models for RNA interference therapeutics. Trump signed a narrower AI oversight executive order requiring a 30-day review before powerful open-weight models can be released. The Trump administration also moved to strip job protections from roughly 8,000 NIH staff, including officials who oversee research grants, while Medicaid work requirements drew criticism for going beyond what advocates had anticipated.

An OpenAI reasoning model disproved an 80-year-old Erdős conjecture in discrete geometry for under $1,000 in compute, a result mathematicians are calling one of the most significant AI contributions to pure math to date. Eli Lilly's retatrutide, a triple-receptor obesity drug, produced bariatric-surgery-level weight loss in a Phase 3 trial, though dropout rates from side effects were notable. Google shipped Gemini 3.5 Flash to general availability at Google I/O and announced a $100 AI Ultra subscription tier. The acting head of NIH's infectious disease institute stepped down as senators pressed NIH Director Jay Bhattacharya on leadership gaps and a proposed 2027 budget cut. Kevin Warsh was confirmed and sworn in as the new Federal Reserve chair this week.

The FDA's leadership vacuum deepened this week as the drug center head followed Commissioner Makary out the door, leaving the agency with no confirmed leadership at its two most critical posts. Open-weight models kept multiplying with Gemma 4, DeepSeek V4, and Kimi K2.6 all dropping in the same month, while Sebastian Raschka's analysis of new KV-sharing and compressed attention techniques explains why long-context costs are falling fast. A rare Bundibugyo Ebola outbreak in Congo's Ituri province prompted a WHO public health emergency declaration, and the WHO's move landed as hantavirus conspiracy theories were already cycling through social media. On the economy side, Trump's China visit produced mixed signals on decoupling, while Noah Smith argued that Europe's comfortable stagnation is no longer viable.